Standout Papers

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic ... 2010 2026 2015 2020 1.0k
  1. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (2010)
    Scott M. Wilhelm, Jacques Dumas et al. International Journal of Cancer

Immediate Impact

2 from Science/Nature 68 standout
Sub-graph 1 of 22

Citing Papers

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies
2025 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
1 intermediate paper

Works of Gunnar Schütz being referenced

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
2010 Standout

Author Peers

Author Last Decade Papers Cites
Gunnar Schütz 78 61 348 516 324 13 1.2k
Annette Frost 74 16 460 736 486 29 1.3k
Haitian Quan 114 21 485 651 375 30 1.3k
Daniel C. Rabe 27 14 624 358 236 24 1.2k
Mark Gimbel 19 3 369 661 154 17 1.0k
Nigel C. Bird 64 3 364 462 149 28 1.1k
J. Rafael Sierra 59 6 571 357 245 18 1.1k
Yihuan Xu 50 2 321 543 232 19 1.0k
Dorothy W. Pan 115 14 225 883 435 25 1.3k
Rakesh R. Ramjiawan 33 5 428 675 218 7 1.3k
Alexander Huether 29 12 427 343 175 12 897

All Works

Loading papers...

Rankless by CCL
2026